시장보고서

상품코드

1511844

일차 세포 시장 규모, 점유율, 동향 분석 리포트 : 유래별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Primary Cells Market Size, Share & Trends Analysis Report By Origin (Human, Animal), By Type (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells), By Application (Regenerative Medicine), By End-use, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

일차 세포 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 일차 세포 시장 규모는 2030년까지 40억 달러에 달하며, 2024-2030년의 CAGR은 10.39%로 성장할 것으로 예측되고 있습니다.

이 시장은 모노클로널 항체에 대한 수요 증가, 암 연구 활성화, 세포주보다 1차 인간 세포에 대한 선호도 증가, 세포 기반 연구에 대한 정부 구상 증가 등으로 인해 성장할 것으로 예상됩니다.

암, 자가면역질환과 같은 만성질환이 전 세계에서 급증함에 따라 모노클로널 항체와 같은 표적치료제에 대한 수요가 증가하고 있습니다. 이러한 바이오의약품은 건강한 세포에 미치는 영향을 최소화하면서 질병에 걸린 세포를 선택적으로 표적화하여 효과적인 치료 접근법을 제공하기 때문에 채택이 증가하고 있습니다. 모노클로널 항체의 생산에는 주로 생체나 조직에서 직접 채취한 세포인 일차 세포가 사용됩니다. 일차 세포는 유래한 조직이나 생물의 유전적, 표현형적 특징을 그대로 가지고 있으므로 생물학적 과정 연구와 항체 생산에 있으며, 보다 확실한 모델이 될 수 있습니다.

또한 인간 일차 세포는 세포치료 분야의 연구개발에서 중요한 역할을 하고 있습니다. 세포 치료는 손상된 조직이나 장기를 대체하거나 복구하기 위해 세포를 이식하는 것으로, 다양한 질병과 질환에 대한 유망한 치료 옵션을 제공합니다. 살아있는 조직에서 직접 얻은 인간 일차 세포는 불멸화 세포주보다 생리학적으로 더 적합한 모델을 제공하여 세포치료 연구에 유용한 툴이 될 수 있습니다. 인간 일차 세포의 HLA 유형과 CMV 상태를 포함한 기증자 간 차이는 개인차가 치료 결과에 영향을 미칠 가능성이 높기 때문에 세포 치료의 맞춤형 의료 접근에 중요합니다. 또한 일차 세포 유도를 전문으로 하는 CRO(Contract Research Organizations)는 연구자들에게 다양한 조직으로부터 일차 세포를 분리하고 준비하는 다양한 서비스를 제공합니다.

주요 세포 시장 보고서 하이라이트

인간 원시세포는 in vivo에서 세포의 생리적 상태에 가깝기 때문에 불멸화 세포주보다 생물학적 관련성이 높은 데이터를 제공할 수 있습니다.
2023년 조혈모세포 유형이 가장 큰 시장 점유율을 차지했습니다. 반면, 골격 및 근육 세포 부문은 2024-2030년 12.51%의 연평균 복합 성장률(CAGR)로 가장 높은 성장률을 보일 것으로 예상됩니다.
2023년에는 암 연구가 용도별 부문을 지배하며 37.74%의 가장 큰 시장 점유율을 차지했습니다. 또한 재생 의학 부문은 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상됩니다.
최종 용도별로는 제약 및 생명공학 기업이 2023년 매출에서 가장 큰 시장 점유율을 차지했습니다.
북미는 암 연구, 세포치료, 맞춤의료, 재생의료 분야에 대한 투자 증가로 인해 36.11%의 매출 점유율로 1차세포 시장을 장악했습니다.

The global primary cells market size is anticipated to reach USD 4.00 billion by 2030, growing at a CAGR of 10.39% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to grow due to the increased demand for monoclonal antibodies, rising cancer research, growing preference for primary human cells over cell lines, and increasing government initiatives for cell-based research.

The surge in chronic diseases globally, such as cancer and autoimmune disorders, has led to a growing demand for targeted therapies like monoclonal antibodies. The adoption of these biopharmaceuticals is on the rise as they offer an effective treatment approach by selectively targeting diseased cells while minimizing the impact on healthy ones. The production of monoclonal antibodies often involves the use of primary cells, which are cells taken directly from living organisms or tissues. Primary cells retain the genetic and phenotypic characteristics of the original tissue or organism from which they were derived, making them more authentic models for studying biological processes and producing antibodies.

Moreover, human primary cells play a crucial role in research and development in the field of cell therapy. Cell therapy involves the transplantation of cells to replace or repair damaged tissues and organs, offering promising treatment options for various diseases and conditions. Human primary cells, derived directly from living tissue, provide a more physiologically relevant model than the immortalized cell lines, making them valuable tools in cell therapy research. Donor-to-donor variability, including HLA type and CMV status, in human primary cells is important for personalized medicine approaches in cell therapy as individual differences are likely to impact treatment outcomes. Furthermore, Contract Research Organizations (CROs) specializing in primary cell derivation provide researchers access to a wide range of services related to isolating and preparing primary cells from diverse tissue sources.

Primary Cells Market Report Highlights:

Human primary cells dominated the origin segment in 2023, owing to their importance in research as they closely resemble the physiological state of cells in vivo, thereby providing more biologically relevant data than immortalized cell lines.
The hematopoietic cells type segment held the largest market share in 2023. On the other hand, skeletal and muscle cells segment is expected to grow at the highest CAGR of 12.51% from 2024 to 2030.
In 2023, cancer research dominated the application segment and held the largest market share of 37.74%. Furthermore, the regenerative medicine segment is expected to grow at the highest CAGR over the forecast period.
Based on end-use, the pharmaceuticals & biotechnology companies segment held the largest market share in terms of revenue in 2023.
North America dominated the market for primary cells with a revenue share of 36.11% owing to the growing investments in the field of cancer research, cell therapies, and personalized and regenerative medicine.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Origin
- 1.2.2. Type
- 1.2.3. Application
- 1.2.4. End-use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape

Chapter 3. Primary Cells Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing demand for monoclonal antibodies
  - 3.2.1.2. Increasing cancer research
  - 3.2.1.3. Increasing government initiatives for cell-based research
  - 3.2.1.4. Growing advantages of primary human cells over cell lines
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Ethical and regulatory concerns related to the use of primary cells
3.3. Industry Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis

Chapter 4. Primary Cells Market: Origin Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Primary Cells Market Origin Movement Analysis
4.3. Global Primary Cells Market Size & Trend Analysis, by Origin, 2018 to 2030 (USD Million)
4.4. Human Primary Cells
- 4.4.1. Human primary cells market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Animal Primary Cells
- 4.5.1. Animal primary cells market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Primary Cells Market: Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Primary Cells Market Type Movement Analysis
5.3. Global Primary Cells Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Hematopoietic Cells
- 5.4.1. Hematopoietic cells market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Skin Cells
- 5.5.1. Skin cells market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Hepatocytes
- 5.6.1. Hepatocytes market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Gastrointestinal Cells
- 5.7.1. Gastrointestinal cells market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Lung Cells
- 5.8.1. Lung cells market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Renal Cells
- 5.9.1. Renal cells market estimates and forecasts 2018 to 2030 (USD Million)
5.10. Heart Cells
- 5.10.1. Heart cells market estimates and forecasts 2018 to 2030 (USD Million)
5.11. Skeletal and Muscle Cells
- 5.11.1. Skeletal and muscle cells market estimates and forecasts 2018 to 2030 (USD Million)
5.12. Other Primary Cells
- 5.12.1. Other primary cells market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Primary Cells Market: Application Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Primary Cells Market Application Movement Analysis
6.3. Global Primary Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Drug Discovery and Development
- 6.4.1. Drug discovery and development market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Regenerative Medicine
- 6.5.1. Regenerative medicine market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Cancer Research
- 6.6.1. Cancer research market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
- 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Primary Cells Market: End-use Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Global Primary Cells Market End-use Movement Analysis
7.3. Global Primary Cells Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
7.4. Pharmaceuticals & Biotechnology companies
- 7.4.1. Pharmaceuticals & Biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Academic and research institutes
- 7.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Contract research organizations
- 7.6.1. Contract research organizations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Primary Cells Market: Regional Estimates & Trend Analysis By Origin, Type, Application, End-Use.

8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
- 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Regulatory framework
  - 8.4.2.3. Competitive scenario
  - 8.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Regulatory framework
  - 8.4.3.3. Competitive scenario
  - 8.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key country dynamics
  - 8.4.4.2. Regulatory framework
  - 8.4.4.3. Competitive scenario
  - 8.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Regulatory framework
  - 8.5.4.3. Competitive scenario
  - 8.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Regulatory framework
  - 8.5.5.3. Competitive scenario
  - 8.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Regulatory framework
  - 8.5.6.3. Competitive scenario
  - 8.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.7. Norway
  - 8.5.7.1. Key country dynamics
  - 8.5.7.2. Regulatory framework
  - 8.5.7.3. Competitive scenario
  - 8.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key country dynamics
  - 8.5.8.2. Regulatory framework
  - 8.5.8.3. Competitive scenario
  - 8.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.9. Denmark
  - 8.5.9.1. Key country dynamics
  - 8.5.9.2. Regulatory framework
  - 8.5.9.3. Competitive scenario
  - 8.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Regulatory framework
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.8. MEA
- 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Regulatory framework
  - 8.8.3.3. Competitive scenario
  - 8.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key country dynamics
  - 8.8.4.2. Regulatory framework
  - 8.8.4.3. Competitive scenario
  - 8.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key country dynamics
  - 8.8.5.2. Regulatory framework
  - 8.8.5.3. Competitive scenario
  - 8.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2023
9.4. Company Profiles/Listing
- 9.4.1. Thermo Fisher Scientific
  - 9.4.1.1. Company overview
  - 9.4.1.2. Financial performance
  - 9.4.1.3. Product benchmarking
  - 9.4.1.4. Strategic initiatives
- 9.4.2. Merck KGaA
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. Lonza
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. Cell Biologics, Inc.
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. PromoCell
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. ZenBio
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. STEMCELL Technologies
  - 9.4.7.1. Company overview
  - 9.4.7.2. Financial performance
  - 9.4.7.3. Product benchmarking
  - 9.4.7.4. Strategic initiatives
- 9.4.8. AllCells
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. American Type Culture Collection
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance
  - 9.4.9.3. Product benchmarking
  - 9.4.9.4. Strategic initiatives
- 9.4.10. Axol Biosciences Ltd.
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product benchmarking
  - 9.4.10.4. Strategic initiatives

일차 세포 시장 규모, 점유율, 동향 분석 리포트 : 유래별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Primary Cells Market Size, Share & Trends Analysis Report By Origin (Human, Animal), By Type (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells), By Application (Regenerative Medicine), By End-use, By Region, And Segment Forecasts, 2024 - 2030

일차 세포 시장의 성장과 동향 :

주요 세포 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 일차 세포 시장 변수, 동향, 범위

제4장 일차 세포 시장 : 유래 추정·동향 분석

제5장 일차 세포 시장 : 유형 추정·동향 분석

제6장 일차 세포 시장 : 용도 추정·동향 분석

제7장 일차 세포 시장 : 최종 용도 추정·동향 분석

제8장 일차 세포 시장 : 유래, 유형, 용도, 최종 용도별 지역 추정·동향 분석.

제9장 경쟁 구도

Primary Cells Market Growth & Trends: